Beyond Air, Inc. (XAIR)

$ 14.4
+0.04 (+0.28%)
-
Symbol XAIR
Price $ 14.4
Beta -0.490
Volume Avg. 0.53M
Market Cap 0.384B
Shares () -
52 Week Range 4.62-16.41
1y Target Est -
DCF Unlevered XAIR DCF ->
DCF Levered XAIR LDCF ->
ROE -67.75% Strong Sell
ROA -38.24% Strong Sell
Operating Margin -
Debt / Equity 32.10% Neutral
P/E -
P/B 8.50 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest XAIR news


Mr. Steven Lisi
Healthcare
Medical Devices
Nasdaq Capital Market

Beyond Air, Inc., a clinical-stage medical device and biopharmaceutical company, develops inhaled nitric oxide (NO) to treat respiratory infections, and gaseous NO to treat solid tumors. The company is developing LungFit system, a NO generator and delivery system, which is in clinical trials for the treatment of lung infections, persistent pulmonary hypertension of the newborn, severe acute respiratory syndrome coronavirus 2, bronchiolitis, and nontuberculous mycobacteria.The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. The company is based in Garden City, New York.